AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1680123 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 65
Study 1680123 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 65
Study 1680123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 6614422 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg buprenorphine
Number of subjects: 40
Study 6614422 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg buprenorphine
Number of subjects: 40
Study 6614422 — intervention group
Group type: COMPARATOR
Intervention: 4 mg morphine
Number of subjects: 40
Study 6614422 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study 6614422 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (both doses)
Number of subjects: 40
Study 30811881 — intervention group
Group type: COMPARATOR
Intervention: CE (finger shapes) technique
Number of subjects: 76
Study 30811881 — intervention group
Group type: EXPERIMENTAL
Intervention: LASOO (Lift, Apply, Slide, Oppose, Observe) technique
Number of subjects: 76
Study 30964968 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare EasyClean power toothbrush with InterCare brush head and AirFloss Pro powered device, used with BreathRx mouthrinse for interdental cleaning (Sonicare Orthodontic Regimen or SOR)
Number of subjects: 223
Study 30964968 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush plus string floss (MTF regimen)
Number of subjects: 223
Study 30964968 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare EasyClean power toothbrush with InterCare brush head and AirFloss Pro powered device, used with BreathRx mouthrinse for interdental cleaning (SOR)
Number of subjects: 223
Study 28558061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose antimony
Number of subjects: 72
Study 28558061 — intervention group
Group type: COMPARATOR
Intervention: High dose antimony
Number of subjects: 72
Study 26775868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional drink (Fresubin Energy®)
Number of subjects: 10
Study 26775868 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of SNEDDS with conventional cinnarizine tablet
Number of subjects: 10
Study 26775868 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 10
Study 25042311 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory taping
Number of subjects: 24
Study 25042311 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory taping
Number of subjects: 24
Study 21929736 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg daily)
Number of subjects: 20
Study 21929736 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 20
Study 21929736 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 20
Study 21929736 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 20
Study 19537366 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (50 units)
Number of subjects: 311
Study 19537366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 17468653 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (9.6 g daily, 3 times a day)
Number of subjects: 663
Study 17468653 — intervention group
Group type: COMPARATOR
Intervention: Control product (0.5 g daily, 3 times a day)
Number of subjects: 663
Study 17468653 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 663
Study 17468653 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 663
Study 15826231 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice (increased exposure to tasks)
Number of subjects: 0
Study 15826231 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacontrast masked primes (used to avoid conscious strategy changes)
Number of subjects: 0
Study 12324304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of beta-carotene, alpha-carotene, beta-cryptoxanthin, lycopene, and lutein + zeaxanthin
Number of subjects: 1452
Study 12324304 — intervention group
Group type: COMPARATOR
Intervention: Subcohort of 5,681 women (noncases)
Number of subjects: 1452
Study 9778325 — intervention group
Group type: EXPERIMENTAL
Intervention: 30000 IU heparin with 10.5 g SNAC
Number of subjects: 0
Study 9778325 — intervention group
Group type: COMPARATOR
Intervention: 30000 IU heparin alone
Number of subjects: 0
Study 9778325 — intervention group
Group type: COMPARATOR
Intervention: 10.5 g SNAC alone
Number of subjects: 0
Study 9778325 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25 g SNAC with heparin 30000 to 150000 IU
Number of subjects: 0
Study 8160257 — intervention group
Group type: EXPERIMENTAL
Intervention: FPIA PF-stimulated saliva (CS)
Number of subjects: 50
Study 8160257 — intervention group
Group type: EXPERIMENTAL
Intervention: ARIS CA-stimulated saliva (CS)
Number of subjects: 50
Study 8160257 — intervention group
Group type: COMPARATOR
Intervention: FPIA CS
Number of subjects: 50
Study 8160257 — intervention group
Group type: COMPARATOR
Intervention: ARIS CS
Number of subjects: 50
Study 8160257 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-stimulated CS
Number of subjects: 50
Study 8160257 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-stimulated CS
Number of subjects: 50
Study 3277664 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carteolol 2%
Number of subjects: 12
Study 3277664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30927032 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27893955 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) high dose
Number of subjects: 60
Study 27893955 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) medium dose
Number of subjects: 60
Study 27893955 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 60
Study 25925415 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate wine consumption (at least 1 glass per day)
Number of subjects: 6973
Study 25925415 — intervention group
Group type: COMPARATOR
Intervention: No significant difference in clinical outcomes
Number of subjects: 6973
Study 23433723 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-led mutual support group
Number of subjects: 135
Study 23433723 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education group
Number of subjects: 135
Study 23433723 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 135
Study 21463064 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective memory performance
Number of subjects: 0
Study 21463064 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived frequency of forgetting
Number of subjects: 0
Study 21463064 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of external aids (calendars, reminder notes)
Number of subjects: 0
Study 18990531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tigecycline
Number of subjects: 418
Study 18990531 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 418
Study 17245175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissucol fibrin glue
Number of subjects: 197
Study 17245175 — intervention group
Group type: COMPARATOR
Intervention: staples
Number of subjects: 197
Study 15133007 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hyperoxic CO2
Number of subjects: 13
Study 15133007 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hyperoxic CO2
Number of subjects: 13
Study 15133007 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 (5% and 7%)
Number of subjects: 13
Study 15133007 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 (7%)
Number of subjects: 13
Study 11769782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to correct refractive errors and cataract surgery
Number of subjects: 0
Study 11769782 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 9233110 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg IV
Number of subjects: 54
Study 9233110 — intervention group
Group type: COMPARATOR
Intervention: Saline solution IV
Number of subjects: 54
Study 7967102 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (quantity in g/week and frequency in times/week)
Number of subjects: 141
Study 7967102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (15 <= cigarette/day < 25)
Number of subjects: 141
Study 7967102 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent intake of fruit
Number of subjects: 141
Study 7967102 — intervention group
Group type: EXPERIMENTAL
Intervention: High-temperature food and drink preference
Number of subjects: 141
Study 7967102 — intervention group
Group type: EXPERIMENTAL
Intervention: Shochu consumption
Number of subjects: 141
Study 12318275 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone rubber uterine probe with reading scale
Number of subjects: 1000
Study 2502065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg
Number of subjects: 53
Study 2502065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 53
Study 2502065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (200 or 400 mg)
Number of subjects: 53
Study 31730088 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferometry-free noncontact photoacoustic detection method based on speckle correlation change
Number of subjects: 0
Study 28328159 — intervention group
Group type: EXPERIMENTAL
Intervention: fosdagrocorat 10 mg
Number of subjects: 86
Study 28328159 — intervention group
Group type: EXPERIMENTAL
Intervention: fosdagrocorat 25 mg
Number of subjects: 86
Study 28328159 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone 5 mg
Number of subjects: 86
Study 28328159 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 25754254 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 30
Study 25754254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24402015 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 117
Study 24402015 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 117
Study 21983008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 27347
Study 21983008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study 21983008 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sexual activity
Number of subjects: 27347
Study 21983008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal atrophy
Number of subjects: 27347
Study 21983008 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and health characteristics
Number of subjects: 27347
Study 19755817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hange-shashin-to
Number of subjects: 20
Study 19755817 — intervention group
Group type: COMPARATOR
Intervention: S-1/Irinotecan (CPT-11) therapy
Number of subjects: 20
Study 16752738 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy added to rehabilitation complex
Number of subjects: 120
Study 16752738 — intervention group
Group type: COMPARATOR
Intervention: Drugs and physiotherapeutic factors
Number of subjects: 120
Study 15315558 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCyte
Number of subjects: 33
Study 15315558 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 33
Study 15315558 — intervention group
Group type: EXPERIMENTAL
Intervention: Silvazine
Number of subjects: 33
Study 11242223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 51
Study 11242223 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative MRI
Number of subjects: 51
Study 11242223 — intervention group
Group type: COMPARATOR
Intervention: Neurologic examination
Number of subjects: 51
Study 9323940 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol hydrochloride 1%
Number of subjects: 176
Study 9323940 — intervention group
Group type: COMPARATOR
Intervention: timolol maleate 0.5%
Number of subjects: 176
Study 7954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg starting dose, increased to 8 mg if DBP > 95 mmHg)
Number of subjects: 47351
Study 7954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 47351
Study 7954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg dose)
Number of subjects: 47351
Study 7954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 47351
Study 7954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough (adverse event)
Number of subjects: 47351
Study 7954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal outcomes
Number of subjects: 47351
Study 3579820 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 2.0 mg
Number of subjects: 20
Study 3579820 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 4.0 mg
Number of subjects: 20
Study 3579820 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.5, 1.0, 2.0, 4.0 mg)
Number of subjects: 20
Study 3579820 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 2.0 mg and 4.0 mg
Number of subjects: 20
Study 30145102 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day bismuth-containing quadruple therapy (group A)
Number of subjects: 105
Study 30145102 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy supplemented with Clostridium butyricum (group B)
Number of subjects: 105
Study 30145102 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative patients (group C)
Number of subjects: 105
Study 26855568 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B patients (COPD GOLD Group B)
Number of subjects: 17135
Study 26855568 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D patients (COPD GOLD Group D)
Number of subjects: 17135
Study 26855568 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A-D (COPD GOLD Groups A-D)
Number of subjects: 17135
Study 25075999 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing (DB)
Number of subjects: 30
Study 25075999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates breathing (PB)
Number of subjects: 30
Study 25075999 — intervention group
Group type: COMPARATOR
Intervention: Natural breathing (NB)
Number of subjects: 30
Study 23077047 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary feedback after initial adaptation
Number of subjects: 0
Study 23077047 — intervention group
Group type: COMPARATOR
Intervention: Visuomotor rotation with error-clamp condition
Number of subjects: 0
Study 23077047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both binary feedback and vector error present
Number of subjects: 0
Study 20093548 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf (Organogenesis, Inc) used in conjunction with standard therapy (sharp debridement, standard wound care, and off-loading)
Number of subjects: 72
Study 20093548 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 72
Study 17538514 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter + test‐request card for a CT urine home sampling kit (arm 1, n = 2940)
Number of subjects: 8820
Study 17538514 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter + mail‐back sampling kit (arm 2, n = 2940)
Number of subjects: 8820
Study 17538514 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (arm 3, n = 2940)
Number of subjects: 8820
Study 16286173 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phenolic virgin olive oil breakfast
Number of subjects: 21
Study 16286173 — intervention group
Group type: COMPARATOR
Intervention: Low-phenolic virgin olive oil breakfast
Number of subjects: 21
Study 14658946 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 366
Study 14658946 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 366
Study 14658946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 10359881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 25
Study 10359881 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 120 mg
Number of subjects: 25
Study 10359881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25
Study 10359881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 25
Study 8532099 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational training for medication management, cognitive therapy, and work with relatives' groups
Number of subjects: 191
Study 8532099 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment including neuroleptic relapse prevention
Number of subjects: 191
Study 1952649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus 22‐channel device
Number of subjects: 82
Study 1952649 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Richards Ineraid device
Number of subjects: 82
Study 1952649 — intervention group
Group type: COMPARATOR
Intervention: 3M/Vienna intracochlear device
Number of subjects: 82
Study 7149218 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 49
Study 7149218 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 49
Study 7149218 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 49
Study 30939851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (60 mg kg‐1 24 h‐¹)
Number of subjects: 54
Study 30939851 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 54
Study 29771088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 1 month
Number of subjects: 160
Study 29771088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 2 months
Number of subjects: 160
Study 29771088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 3 months
Number of subjects: 160
Study 29771088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 4 months
Number of subjects: 160
Study 29771088 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study 26917577 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy (2 g/day for 1 month)
Number of subjects: 52
Study 26917577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23961951 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site with a single channel varicocele ligation (LESS[sc]‐VL)
Number of subjects: 90
Study 23961951 — intervention group
Group type: COMPARATOR
Intervention: Conventional transperitoneal laparoscopic varicocele ligation (CTL‐VL)
Number of subjects: 90
Study 22138866 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCHO; 7 g/kg body weight)
Number of subjects: 10
Study 22138866 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet (LCHO; 2 g/kg body weight)
Number of subjects: 10
Study 20667682 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Number of subjects: 28
Study 20667682 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 28
Study 17977274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thalamic deep brain stimulation (DBS)
Number of subjects: 5
Study 15743362 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h
Number of subjects: 42
Study 15743362 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin 2 mg intravenous bolus
Number of subjects: 42
Study 12542199 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppository)
Number of subjects: 14
Study 12542199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9469362 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg/day administered subcutaneously on days 3 through 9 after each BOP and on days 6 through 19 after each VIP, BEP, or EP cycle
Number of subjects: 250
Study 9469362 — intervention group
Group type: COMPARATOR
Intervention: Not receiving filgrastim (control group)
Number of subjects: 250
Study 9469362 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 250
Study 7630200 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplant in first remission for patients < 40 years old
Number of subjects: 149
Study 7630200 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone for patients < 40 years old
Number of subjects: 149
Study 2118326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1-g doses, three postoperative)
Number of subjects: 138
Study 2118326 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1-g single dose preoperative)
Number of subjects: 138
Study 2118326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin and Ceftriaxone
Number of subjects: 138
Study 318965 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of terbutaline sulfate
Number of subjects: 49
Study 318965 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg of epinephrine hydrochloride
Number of subjects: 49
Study 31326778 — intervention group
Group type: EXPERIMENTAL
Intervention: Asserted evidence of effectiveness
Number of subjects: 7058
Study 31326778 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantification of policy effectiveness
Number of subjects: 7058
Study 31326778 — intervention group
Group type: EXPERIMENTAL
Intervention: Labelling policy
Number of subjects: 7058
Study 31326778 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability policy
Number of subjects: 7058
Study 31326778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 7058
Study 31326778 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 7058
Study 31326778 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie snack food consumption
Number of subjects: 7058
Study 31326778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no message)
Number of subjects: 7058